Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (Nasdaq: GERN) is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. News about Geron frequently centers on its first-in-class telomerase inhibitor RYTELO (imetelstat), which is approved in the United States and the European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia.
On this page, readers can follow corporate announcements and scientific updates that shape the GERN investment story. Typical news items include financial guidance and quarterly results that discuss RYTELO net product revenue and operating expenses, strategic restructuring plans intended to support the company’s hematology focus, and details of equity grants made under Nasdaq inducement award rules. These disclosures provide insight into Geron’s commercial execution, cost structure and capital allocation.
Geron also issues frequent clinical and medical conference updates. Recent releases have highlighted data presented at the American Society of Hematology (ASH) Annual Meeting, including pooled analyses from the Phase 3 IMerge trial in LR-MDS, long-term outcomes data, and exploratory biomarker studies in myelofibrosis and advanced myelodysplastic neoplasms or acute myeloid leukemia. News about the IMpactMF Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis, as well as the IMbark, IMproveMF and IMpress studies, offers additional context on imetelstat’s development across myeloid malignancies.
Investors can also track leadership changes and investor relations events, such as executive appointments, board updates and participation in healthcare investor conferences. Together, these news items help explain how Geron is pursuing its stated priorities of driving RYTELO commercial growth, expanding access in LR-MDS markets outside the U.S. and advancing its pivotal myelofibrosis program. Bookmark this page to follow ongoing developments affecting GERN’s clinical programs, regulatory milestones, commercial performance and corporate strategy.
Geron (Nasdaq: GERN) provided 2026 financial guidance forecasting RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. The company expects top-line growth driven by focused U.S. commercial efforts and stronger second-half performance, plus year‑over‑year operating expense reduction following a strategic restructuring. Geron also noted expanded clinical evidence for RYTELO in LR‑MDS and amended its 5‑year senior secured term loan to extend the outside date for Tranche B ($75M) and Tranche C ($50M) to July 30, 2026.
Geron (Nasdaq: GERN) announced an inducement equity grant effective Dec 17, 2025 for a newly hired employee: 320,000 stock options with an $1.34 exercise price (equal to the grant-date close).
The options have a 10-year term and vest over 4 years (12.5% at the six-month anniversary, then remaining shares vesting in equal monthly whole-share installments over the next 42 months). Grants were approved under Nasdaq Listing Rule 5635(c)(4) and the company’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced a strategic restructuring on Dec. 11, 2025 to sharpen its U.S. RYTELO commercial strategy and prioritize clinical development, including the Phase 3 IMpactMF trial. The plan targets an approximately one-third reduction of the company’s ~260-employee workforce and is expected to be substantially complete in Q1 2026.
Management expects initial projected full-year 2026 operating expenses to be lower than projected 2025 expenses, with savings beginning in Q1 2026. Geron will incur restructuring charges, primarily cash-based, and said it will disclose additional details in a Form 8-K filed with the SEC.
Geron (Nasdaq: GERN) presented pooled and long-term data at ASH 2025 on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis. Post-hoc pooled IMerge analyses linked early treatment-emergent neutropenia and thrombocytopenia in the first two cycles to greater hemoglobin increases and higher rates of red blood cell transfusion independence.
At a median follow-up of 45 months, IMerge showed a favorable trend in overall survival, PFS, and time to AML progression versus placebo though the trial was not powered for OS. Additional ASH data include dose-dependent cytokine reductions in IMbark and a recommended combinational dose of 8.9 mg/kg from IMproveMF.
Geron (Nasdaq: GERN) reported Q3 2025 results and business highlights on November 5, 2025. RYTELO net product revenue was $47.2M in Q3 2025 versus $28.2M in Q3 2024. The company completed enrollment of 320 patients in the Phase 3 IMpactMF trial and expects an interim overall survival analysis in 2H 2026 and a final analysis in 2H 2028. Cash and marketable securities were approximately $421.5M at September 30, 2025.
Q3 net loss narrowed to $18.4M ($0.03/share) from $26.4M a year earlier. 2025 operating expense guidance was revised lower to $250–$260M. Leadership additions include a new Chief Commercial Officer and other executive hires. The company will present data at ASH 2025 and hosted a conference call on November 5, 2025.
Geron Corporation (Nasdaq: GERN) announced that CEO Harout Semerjian will present at two investor conferences in November–December 2025. He will appear in a fireside chat at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 11:40 AM ET in New York, and at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 11:15 AM ET in Miami. A live webcast of each fireside chat will be available in the company’s Investors & Media Events section, and replays will be archived on the company website.
Geron (Nasdaq: GERN) announced five presentations accepted for ASH 2025 (Dec 6-9, Orlando) reporting new clinical and translational analyses of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF).
Highlights include an oral IMerge Phase 3 analysis linking treatment-emergent cytopenias to clinical response in LR-MDS (Dec 7), a long-term IMerge poster with a ≥42-month overall survival trend versus placebo (Dec 6), MF biomarker and cytokine-response analyses from IMbark, an IMproveMF combination trial update, and an investigator-led interim IMpress study in high-risk MDS/AML.
Geron (Nasdaq: GERN) will release its third quarter 2025 financial results and business highlights before the market opens on Wednesday, November 5, 2025.
The company said the results will be posted via press release on its investor website and that management will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day. A live webcast and related presentation will be available and archived on the investor site for later playback.
Geron (Nasdaq: GERN) reported inducement equity awards to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
On October 17, 2025 Geron granted awards covering 1,579,500 shares (1,553,000 stock options and 26,500 RSUs). On October 20, 2025 Geron granted awards covering 1,500,000 shares to one new hire. Options from October 17 carry an exercise price of $1.20; options from October 20 carry an exercise price of $1.27—each equal to the closing price on the grant date.
Options have a 10-year term and vest over 4 years (12.5% at six months, then monthly over 42 months). RSUs vest 25% annually over four years. Awards were granted by the Compensation Committee under Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced executive leadership transitions on Oct 13, 2025. Andrew Grethlein (EVP, COO) and Jim Ziegler (EVP, CCO) will depart on Oct 15, 2025, with Grethlein moving to a consulting role. Effective Oct 20, 2025, Ahmed ElNawawi is appointed EVP, Chief Commercial Officer to lead U.S. commercial strategy for RYTELO. Three additional senior hires announced: Shantha Tyavanagimatt as SVP, Chief Technical Officer; Dawn Schottlandt as SVP, Investor Relations and Corporate Affairs; and Bryan Ridgell as SVP, Portfolio and Project Management and Chief of Staff (joined Oct 13, 2025).
The appointments emphasize commercial scale-up, technical operations, investor engagement, and portfolio management to support RYTELO commercialization and future portfolio expansion.
FAQ
What is the current stock price of Geron (GERN)?
What is the market cap of Geron (GERN)?
